BTX 1503
Acne (in adults and teenagers)
Clinical DevelopmentActive program targeting sebum overproduction, inflammation, and bacterial infection
Key Facts
Indication
Acne (in adults and teenagers)
Phase
Clinical Development
Status
Active program targeting sebum overproduction, inflammation, and bacterial infection
Company
About Botanix Pharmaceuticals
Botanix Pharmaceuticals is a global healthcare innovator focused on transforming the treatment landscape for common yet underserved dermatological conditions and infections. The company's key achievement is the FDA approval and US commercial launch of Sofdra™, its first-in-class topical anticholinergic for hyperhidrosis, which is also approved and launched in Japan and South Korea through partners. With a mature pipeline targeting acne, rosacea, atopic dermatitis, and antimicrobial resistance (MRSA), and led by a world-class team with extensive dermatology drug development and commercialization expertise, Botanix is strategically positioned to capture significant market opportunities.
View full company profile